Fibrolamellar Carcinoma Overview

Save information for later
Sign Up

Learn About Fibrolamellar Carcinoma

What is the definition of Fibrolamellar Carcinoma?
Many people with early FLC have no signs or symptoms of the condition. When present, symptoms are often nonspecific (i.e. abdominal pain, weight loss, malaise) and blamed on other, more common conditions. The exact underlying cause of FLC is poorly understood. Unlike other forms of liver cancer, FLC typically occurs in the absence of underlying liver inflammation or scarring; thus, specific risk factors for this condition remain unidentified.
What are the alternative names for Fibrolamellar Carcinoma?
  • Fibrolamellar carcinoma
  • Eosinophilic glassy cell hepatoma
  • Eosinophilic hepatocellular carcinoma with lamellar fibrosis
  • FHCC
  • FL-HCC
  • Fibrolamellar hepatocarcinoma
  • Fibrolamellar hepatocellular carcinoma
  • Fibrolamellar oncocytic hepatoma
  • Hepatocellular carcinoma with increased stromal fibrosis
  • Polygonal cell hepatocellular carcinoma with fibrous stroma
Who are the top Fibrolamellar Carcinoma Local Doctors?
Experienced in Fibrolamellar Carcinoma
Dr. Chandler H. Park
Hematology Oncology | Hematology | Oncology
Experienced in Fibrolamellar Carcinoma
Dr. Chandler H. Park
Hematology Oncology | Hematology | Oncology

Norton Hospitals Inc

245 Atwood St, 
Corydon, IN 
 (14.3 mi)
812-734-0912
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Chandler Park is a Hematologist Oncology specialist and a Hematologist in Corydon, Indiana. Dr. Park and is rated as an Experienced provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Chromophobe Renal Cell Carcinoma, Familial Wilms Tumor 2, WT1-Related Wilms Tumor Syndromes, and Choriocarcinoma. Dr. Park is currently accepting new patients.

Experienced in Fibrolamellar Carcinoma
Dr. Erik E. Dowden
Radiology
Experienced in Fibrolamellar Carcinoma
Dr. Erik E. Dowden
Radiology

Vip Imaging PLLC

1011 Old Hwy 60, 
Hardinsburg, KY 
 (21.8 mi)
502-432-2299
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Erik Dowden is a Radiologist in Hardinsburg, Kentucky. Dr. Dowden and is rated as an Experienced provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Visceromegaly, ALK-Positive Non-Small Cell Lung Cancer, Vertigo, and Progressive Familial Intrahepatic Cholestasis Type 2. Dr. Dowden is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in Fibrolamellar Carcinoma
Dr. Donald E. Goodin
Hematology Oncology | Hematology | Oncology
Experienced in Fibrolamellar Carcinoma
Dr. Donald E. Goodin
Hematology Oncology | Hematology | Oncology

Baptist Health Medical Group Inc

521 Robinbrooke Blvd, 
Elizabethtown, KY 
 (23.9 mi)
270-706-1535
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Donald Goodin is a Hematologist Oncology specialist and a Hematologist in Elizabethtown, Kentucky. Dr. Goodin and is rated as an Experienced provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), and Lung Cancer. Dr. Goodin is currently accepting new patients.

View All Doctors
What are the latest Fibrolamellar Carcinoma Clinical Trials?
A Phase 1b/2 Study of Glutamine Antagonist DRP-104 in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Hepatocellular Carcinoma (FLC)
A Phase 1b/2 Study of Glutamine Antagonist DRP-104 in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Hepatocellular Carcinoma (FLC)
Enrollment Status: Recruiting
Publish Date: February 21, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: The purpose of this study is to determine whether the combination of subcutaneous DRP-104 in combination with intravenous Durvalumab is safe and yields a clinically compelling antitumor activity measured as based on objective response rate (ORR, assessed by RECIST 1.1). Secondary objectives include progression-free survival (PFS) and overall survival (OS).

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase I/II Study of Nivolumab Plus 5-Fluorouracil Plus Interferon-α2b for Unresectable Fibrolamellar Hepatocellular Carcinoma
A Phase I/II Study of Nivolumab Plus 5-Fluorouracil Plus Interferon-α2b for Unresectable Fibrolamellar Hepatocellular Carcinoma
Who is this study for: Patients with Hepatocellular Carcinoma
Enrollment Status: Recruiting
Publish Date: February 11, 2025
Intervention Type: Drug, Biological
Study Drugs: Fluorouracil, Nivolumab, Recombinant Interferon Alpha 2b-like Protein
Study Phase: Phase 1/Phase 2

Summary: This phase I/II trial studies the side effects and how well nivolumab, fluorouracil, and interferon alpha 2b work for the treatment of fibrolamellar cancer (liver cell cancer) that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center